Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies (Preprint)
Authors:
- Nana A MensahNMNana A Mensah
- Michael J FassettMFMichael J Fassett
- Nehaa KhadkaNKNehaa Khadka
- Jiaxiao M ShiJSJiaxiao M Shi
- Fagen XieFXFagen Xie
- Vicki Y ChiuVCVicki Y Chiu
- Theresa M ImTITheresa M Im
- Sunhea KimSKSunhea Kim
- Daniella ParkDPDaniella Park
- Carol MaoCMCarol Mao
- Matthew MolaeiMMMatthew Molaei
- Iris LinILIris Lin
Preprint
- 21 May 2025
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. OBJECTIVE This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. METHODS We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processing–assisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. RESULTS The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. CONCLUSIONS We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processing–assisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77836Keywords
All Related Versions
- Published version: JMIR Research Protocols, 14, e77836.
This publication has 27 references indexed in Scilit:
- Identifying Hemolytic Disease of the Fetus and Newborn within a Large Integrated Health Care SystemAmerican Journal of Perinatology, 2024
- Fine Particulate Matter, Its Constituents, and Spontaneous Preterm BirthJAMA Network Open, 2024
- Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010AJOG Global Reports, 2023
- Retrospective analysis of direct antiglobulin test positivity at tertiary academic hospital over 10 yearsTransfusion and Apheresis Science, 2022
- The rhesus incompatible pregnancy and its consequences for affected fetuses and neonatesTransfusion and Apheresis Science, 2020
- A systematic review of validated methods to capture several rare conditions using administrative or claims dataVaccine, 2013
- Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunizationEarly Human Development, 2011
- Diagnostic Laboratory Technologies for the Fetus and Neonate with IsoimmunizationSeminars in Perinatology, 2011
- Fetal anemia due to non-Rhesus-D red-cell alloimmunizationSeminars in Fetal and Neonatal Medicine, 2008
- RhD haemolytic disease of the fetus and the newbornBlood Reviews, 2000